Cosmos Health Begins Commissioning Automated CosmoFarm Distribution Infrastructure
Cosmos Health says its CosmoFarm subsidiary is commissioning automated order-processing and vehicle-loading infrastructure at its Peristeri distribution centre, while a proposed acquisition remains at the letter of intent stage.
Cosmos Health Inc. announced on November 5, 2026 that its wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A., is commissioning automated order-processing and vehicle-loading infrastructure at its distribution centre in Peristeri, western Athens. The equipment is intended to move pharmacy orders through the facility and onto delivery vehicles more quickly.
The order-processing installation includes an automated handling cell supplied by a roller conveyor. Engineers are configuring and testing the equipment at the site, where it is intended to automate the handling of orders before dispatch.
CosmoFarm has also installed multiple rows of inclined roller flow lanes for moving completed orders onto delivery vehicles. The company says the combined systems are designed to reduce processing and loading times, allowing vehicles to leave earlier and supporting earlier deliveries to pharmacies.
Cosmos Health expects to report operational results after the infrastructure is fully operational.
CosmoFarm had reached a previously disclosed annualized revenue run-rate of over $60 million based on second-quarter 2026 revenue, with the company saying momentum continued into the third quarter. The run-rate is calculated from second-quarter 2026 revenue and takes into account third-quarter 2026 results. The figures are based on management data, are preliminary and unaudited, and the annualized run-rate is not a forecast.
CosmoFarm serves approximately 360 pharmacies daily within a network of more than 1,500. Cosmos Health says the faster systems are expected to create capacity to add more pharmacies to established routes at limited incremental cost.
Cosmos Health believes that CosmoFarm’s platform could support over $120 million in annual revenue through its investments in robotics, automation and artificial intelligence, including the new infrastructure.
The company describes this figure as a management estimate based on current expectations. It says actual results may differ materially. The announcement also notes that expected improvements and revenue capacity are management estimates, while U.S. dollar figures reflect changes in the euro/U.S. dollar exchange rate.
CosmoFarm has an active letter of intent covering the potential acquisition of a distribution network with approximately €10 million (approximately $11.3 million) in annual gross revenue. The target is owned by an established pharmaceutical company that has served the Greek market for almost 40 years.
The transaction remains subject to a definitive agreement and customary closing conditions, and Cosmos Health stated that there can be no assurance it will be completed. If completed, the acquisition would be CosmoFarm’s largest acquisition to date.
The proposed transaction forms part of CosmoFarm’s consolidation strategy in Greece’s fragmented pharmaceutical wholesale market. Since 2019, the subsidiary has completed multiple bolt-on acquisitions of regional distribution networks and integrated their customers onto its automated platform.
Cosmos Health said the Peristeri installations are part of a multi-year programme involving robotics, automation and artificial intelligence. Its forward-looking statements remain subject to risks including financing needs, the timing, cost and completion of planned capital investments, foreign exchange movements, legal and regulatory changes, international operating challenges and the completion of potential transactions.
The company said forward-looking statements are not guarantees of future performance and that actual results could differ materially from its expectations.
CosmoFarm is commissioning automated order-processing and vehicle-loading infrastructure at its distribution centre in Peristeri, Athens.
The systems are designed to shorten processing and loading times and allow delivery vehicles to depart earlier.
CosmoFarm reported an annualized revenue run-rate of over $60 million based on second-quarter 2026 revenue; the figure is preliminary, unaudited and not a forecast.
Cosmos Health believes the platform could support over $120 million in annual revenue, but this remains a management estimate.
A proposed acquisition involving approximately €10 million (approximately $11.3 million) in annual gross revenue remains subject to a definitive agreement and customary closing conditions.
Cosmos Health announced that its wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A., is commissioning new automated order-processing and vehicle-loading infrastructure at its distribution centre in Peristeri, western Athens. The equipment is designed to move pharmacy orders through the facility and onto delivery vehicles faster.
The new infrastructure includes an automated handling cell fed by a roller conveyor, which is being configured and tested on site. It is designed to automate the handling of orders ahead of dispatch.
CosmoFarm has installed multiple rows of inclined roller flow lanes to speed the movement of completed orders onto delivery vehicles. The company says the installations are designed to reduce processing and loading times, allowing vehicles to depart earlier and supporting earlier pharmacy deliveries.
Cosmos Health expects to report operational results once the new infrastructure is fully up and running. The announcement says the equipment is still being configured and tested on site.
CosmoFarm had reached a previously disclosed annualized revenue run-rate of over $60 million based on second-quarter 2026 revenue, with momentum continuing into the third quarter. The figures are based on management data, are preliminary and unaudited, and the annualized run-rate is not a forecast.
CosmoFarm serves approximately 360 pharmacies daily within a network of more than 1,500. Cosmos Health says faster processing and loading are expected to allow CosmoFarm to add more pharmacies to established routes at limited incremental cost.
Cosmos Health believes the CosmoFarm platform could support over $120 million in annual revenue through its investments in robotics, automation and artificial intelligence, including the new infrastructure. This is a management estimate based on current expectations; actual results may differ materially.
CosmoFarm has an active letter of intent to acquire a network with approximately €10 million (approximately $11.3 million) in annual gross revenue. The target is owned by an established pharmaceutical company that has served the Greek market for almost 40 years.
The acquisition remains at the letter of intent stage and is subject to a definitive agreement and customary closing conditions. Cosmos Health states that there can be no assurance that it will be completed.
If completed, the acquisition would be CosmoFarm’s largest acquisition to date. The announcement also says the added capacity supports CosmoFarm’s strategy of consolidating regional distribution networks in Greece’s fragmented pharmaceutical wholesale market.
Cosmos Health says the new infrastructure is part of a multi-year programme in robotics, automation and artificial intelligence. The company also says CosmoFarm has completed multiple bolt-on acquisitions of regional distribution networks since 2019 and integrated their customers onto its automated platform.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group with proprietary pharmaceutical and nutraceutical brands, manufacturing operations through Cana Laboratories S.A., pharmaceutical and parapharmaceutical distribution subsidiaries in Greece and the UK, research and development partnerships, and a telehealth business through ZipDoctor, Inc. CosmoFarm is its wholly owned pharmaceutical distribution subsidiary.
Cosmos Health identifies its shares as listed on Nasdaq under the ticker symbol COSM, written in the source as NASDAQ: COSM.
Cosmos Health says its forward-looking statements are subject to risks including its ability to raise sufficient financing, the timing, cost and completion of planned capital investments, challenges of operating in international markets, legal and regulatory changes, foreign exchange movements, and the completion of potential transactions. The company states that these statements are not guarantees of future performance and that actual results could differ materially from its expectations.